A pancreatic cancer blood test cannot, on its own, tell you whether a new targeted drug is an option for you. That distinction became concrete on August 26, 2026, when the U.S. Food and Drug Administration approved Rasonque (daraxonrasib), the first RAS inhibitor for the most common form of pancreatic cancer. The approval covers adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic therapy, or who cannot receive multiagent chemotherapy. In this article you will learn what the decision covers, which laboratory analyses actually surround a pancreatic diagnosis, what the CA 19-9 marker can and cannot do, and how to read an abnormal pancreatic panel calmly.
What the FDA approved on August 26, 2026
Rasonque is a once-daily tablet that targets multiple forms of a protein called RAS. RAS acts like a switch inside the cell: when a mutation jams it in the “on” position, the cell keeps dividing. That jammed switch drives tumor growth in most pancreatic adenocarcinomas, which arise from the cells lining the ducts of the pancreas.
In the randomized trial that supported the decision, 500 adults with previously treated metastatic disease received either the new tablet or standard chemotherapy. Median overall survival was 13.2 months with the drug, compared with 6.7 months with chemotherapy. The FDA granted the approval 6.5 months ahead of its own deadline, under breakthrough therapy and orphan drug designations. Reported side effects include rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, reduced appetite and bleeding.
Two points deserve emphasis. This is a treatment for advanced disease, not a screening tool and not a cure. And it does not change how pancreatic cancer is found in the first place.
Why laboratory analysis decides who is eligible
Targeted drugs are prescribed on the basis of what a tumor is made of, not on symptoms. Before a RAS-directed treatment is considered, an oncology team confirms the diagnosis on tissue, stages the disease with imaging, and characterizes the tumor molecularly. Molecular profiling can be performed on a tissue biopsy or, increasingly, on a blood sample that captures fragments of tumor DNA circulating in plasma.
This is where a pancreatic cancer blood test enters the picture, and where its limits also become visible. A routine panel drawn at your local laboratory does not perform molecular profiling. It measures enzymes, liver markers and, sometimes, a tumor marker. Those results can raise a question. They cannot answer it.
The laboratory analyses that surround a pancreatic diagnosis
Several routine analyses are ordered when the pancreas is under suspicion. Each one answers a narrow question, and none is diagnostic alone.
| Analisi | Cosa misura | What it is actually used for |
|---|---|---|
| Lipase and amylase | Digestive enzymes released by the pancreas | Detecting inflammation of the pancreas, not cancer |
| Total and direct bilirubin | A yellow pigment processed by the liver | Signalling a blocked bile duct, a frequent early clue |
| Fosfatasi alcalina | An enzyme found in liver and bile ducts | Supporting the same obstruction question as bilirubin |
| CA 19-9 | A protein made by some digestive tumors | Following an established cancer over time |
| Glicemia a digiuno e HbA1c | Blood sugar now and over three months | Tracking diabetes that can appear alongside pancreatic disease |
| Molecular profiling | Mutations in tumor tissue or circulating tumor DNA | Matching a confirmed cancer to a targeted therapy |
Our library explains in plain language gli enzimi pancreatici amilasi e lipasi. A separate page covers in more detail the interpretation of lipase levels. If jaundice is part of the picture, you can also read our guide to total bilirubin levels, then consult our page about the alkaline phosphatase test.
CA 19-9: useful for monitoring, unreliable for screening
CA 19-9 is the tumor marker most often associated with the pancreas, and it is also the most misunderstood. According to the National Library of Medicine, high levels can accompany cancers of the pancreas, bile duct, colon, stomach, ovaries or bladder, but they also rise in gallstones, cholangitis, pancreatitis, cirrhosis and cystic fibrosis. A raised value in a healthy person is not a cancer diagnosis.
The reverse is equally true. Roughly 5 to 10 percent of people carry a blood group variant that prevents them from producing CA 19-9 at all, so a normal result in that group tells you nothing. This is why clinicians use the marker mainly to follow a cancer already confirmed: falling values suggest treatment is working, rising values prompt further investigation. Our detailed page covers the interpretation of the CA 19-9 blood test. A broader article explains the general logic behind tumor markers.
When an abnormal pancreatic panel should prompt a consultation
Most abnormal enzyme or liver results have benign explanations. A few combinations deserve prompt medical attention rather than watchful waiting:
- Yellowing of the skin or eyes, dark urine and pale stools, especially with rising bilirubin.
- Severe, persistent upper abdominal pain radiating to the back, with a sharply raised lipase.
- Unexplained weight loss over a few weeks alongside any abnormal pancreatic result.
- New-onset diabetes after age 50 in someone without the usual risk factors.
- A CA 19-9 result requested outside any diagnosed condition, which is rarely informative on its own.
None of these signs proves cancer. They justify a conversation with a physician and, usually, imaging. Our overview describes the symptoms and diagnosis of pancreatic cancer. Another page details the warning signs of pancreatitis, e un articolo correlato spiega what to do about abnormal blood test results.
Ultimi progressi scientifici
Research published in the past two years helps put this approval in context, in plain terms.
The pivotal study behind the approval, known as RASolute 302, was a phase 3 trial run in 60 centers and registered on the U.S. clinical trials registry. A phase 3 trial is the large, final comparison stage before regulators decide. Specialists reviewing the results in 2026 described a roughly doubled median survival in second-line treatment compared with chemotherapy, and called it a shift in what is possible for a cancer where options had barely moved for years. What this means for you: for people with advanced disease who have already had chemotherapy, there is now a second option where there was essentially one.
A 2026 review of the same drug family adds a caution worth keeping. Researchers report that tumors can eventually adapt and stop responding, and that skin and mucous membrane side effects remain a real constraint. The authors also note that follow-up increasingly relies on liquid biopsies, meaning repeated blood samples that look for tumor DNA. What this means for you: response to these treatments is monitored, not assumed.
Two studies published in a surgical journal in 2026 tackle the CA 19-9 blind spot directly. One evaluated an alternative marker, DUPAN-2, in patients who do not produce CA 19-9, and found that normal levels after treatment tracked with better outcomes. The other trained an algorithm on routine laboratory data to build a substitute marker for the same group. Both remain research tools rather than routine practice. What this means for you: the gap left by a non-informative CA 19-9 is a recognized problem that laboratory medicine is actively working on.
Finally, a 2024 systematic review of liquid biopsy in pancreatic cancer concluded that detecting mutant KRAS in circulating tumor DNA shows genuine promise, particularly for residual disease, while broader early detection is not yet validated. What this means for you: a blood test that reliably finds pancreatic cancer early does not exist today. We reviewed the same question for broader screening panels in our analysis of lo studio 2026 sulla diagnosi precoce di tumori multipli.
Glossario
| Termine | Definizione |
|---|---|
| Adenocarcinoma | A cancer that starts in gland-like cells. In the pancreas it arises from the cells lining the ducts. |
| RAS | A family of proteins acting as growth switches inside cells. Mutations lock the switch on. |
| KRAS | The RAS gene most often mutated in pancreatic cancer. |
| Marcatore tumorale | A substance measurable in blood that may rise with cancer, but also with other conditions. |
| CA 19-9 | Carbohydrate antigen 19-9, the tumor marker most used to follow pancreatic and bile duct cancers. |
| Biopsia liquida | A blood sample analyzed for fragments of tumor DNA, instead of taking tissue. |
| DNA tumorale circolante | Small pieces of DNA shed by a tumor into the bloodstream. |
| Metastatico | Describing a cancer that has spread beyond the organ where it started. |
| Overall survival | The length of time patients live after starting a treatment, measured in a trial. |
| Molecular profiling | Laboratory analysis identifying the mutations present in a tumor. |
Domande frequenti
Can a blood test detect pancreatic cancer early?
Not reliably, and not today. No blood analysis is validated for screening the general population for pancreatic cancer. Enzymes such as lipase and markers such as CA 19-9 can be normal in early disease and abnormal in benign conditions. Research on circulating tumor DNA is promising for following a known cancer, but it has not been shown to detect the disease early enough, and accurately enough, to be used as a screening test. Diagnosis still relies on imaging and a tissue sample.
Does the new drug require a genetic test before it can be prescribed?
The approval covers adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy or cannot receive multiagent chemotherapy. In practice, oncology teams characterize the tumor molecularly before choosing a targeted treatment, using tissue or a blood-based analysis. Your oncologist decides which analyses are needed in your specific situation.
My CA 19-9 came back slightly high. Should I be worried?
A mildly elevated CA 19-9 in someone without symptoms is far more often explained by gallstones, bile duct inflammation, pancreatitis or liver disease than by cancer. Healthy people can also have raised levels. The value is interpreted alongside your history, examination and, if needed, imaging. Bring the result to your physician rather than acting on the number alone.
Is this treatment available outside the United States?
The August 2026 decision applies to the United States. Availability elsewhere depends on each country’s own regulatory review and reimbursement process, which follows a separate timeline. Patients outside the United States should ask their oncology team about local access and about ongoing clinical trials.
Why do amylase and lipase matter if they do not detect cancer?
They measure inflammation of the pancreas. A sharply raised lipase points toward pancreatitis, which is common and usually unrelated to cancer, but which shares symptoms with it. Ruling pancreatitis in or out helps a physician decide whether imaging is needed and how urgently.
Can new-onset diabetes be a sign of pancreatic disease?
It can be, in a minority of cases. Diabetes appearing after age 50 in a person without typical risk factors, particularly with weight loss, is one of the situations physicians take seriously. Most new diabetes has ordinary causes, so this is a reason to be evaluated, not a reason to assume the worst.
Fonti
- U.S. Food and Drug Administration — FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer, August 26, 2026 — fda.gov
- National Library of Medicine, MedlinePlus — CA 19-9 Blood Test (Pancreatic Cancer), 2026 — medlineplus.gov
- National Cancer Institute — Pancreatic Cancer Treatment (PDQ), patient version — cancer.gov
- Pillozzi S, Giommoni E, Petroni G, et al. — The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026 — Journal of Hematology and Oncology, 2026 — doi.org/10.1186/s13045-026-01834-2
- Honda R. — Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies — Cancer Science, 2026 — doi.org/10.1111/cas.70497
- Omiya K, Oba A, Tanaka K, et al. — Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer — JAMA Surgery, 2026 — doi.org/10.1001/jamasurg.2026.1810
- Thalji SZ, Aldakkak M, Ramamurthi A, et al. — AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma — JAMA Surgery, 2026 — doi.org/10.1001/jamasurg.2026.0291
- Munnings R, et al. — Evolution of Liquid Biopsies for Detecting Pancreatic Cancer — Cancers, 2024 — consensus.app
- ClinicalTrials.gov — RASolute 302: A Phase 3 Study of Daraxonrasib Versus Standard of Care in Previously Treated Metastatic PDAC, NCT06625320 — clinicaltrials.gov
Approfondimenti
- CA 19-9 alto: cosa significa il tuo risultato
- Pancreatic cancer: symptoms, diagnosis and treatment
- I marcatori tumorali spiegati: cosa misurano e quali sono i loro limiti
- Pancreatitis: symptoms, causes and when to worry
- Test di diagnosi precoce multi-tumore: cosa ha rivelato davvero lo studio del 2026
Scopri i tuoi referti con AI DiagMe
A pancreatic result rarely speaks for itself. Lipase, amylase, bilirubin, alkaline phosphatase and CA 19-9 only make sense together, and against your own history. AI DiagMe reads your laboratory report and explains, in ordinary language, what each value measures and which combinations deserve a medical opinion. It helps you understand your results and prepare your questions; it does not diagnose and does not replace your physician.
Ottieni l'interpretazione dei tuoi risultati in pochi minuti
